Access cutting-edge pneumococcal disease treatment through this clinical trial at a research site in Sioux City. Study-provided care at no cost to qualified participants.
Access pneumococcal disease specialists in Sioux City at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pneumococcal disease treatment provided free
The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and 6 to 17 YoA-years of age).
Sponsor: Sanofi Pasteur, a Sanofi Company
Check if you qualify for this pneumococcal disease clinical trial in Sioux City, IA
If you're searching for pneumococcal disease treatment options in Sioux City, IA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Sioux City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pneumococcal disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.